FOLH1 and prostate cancer: On the basis of this work, Hiller et al. [17] did the preclinical evaluation of two radiopharmaceuticals, 123I-MIP-1072 and 123I-MIP-1095, that were designed to target PSMA in prostate cancer cells and tissue.